Innocan Pharma Corp
CNSX:INNO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Innocan Pharma Corp
Accounts Payable
Innocan Pharma Corp
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Innocan Pharma Corp
CNSX:INNO
|
Accounts Payable
$235k
|
CAGR 3-Years
35%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Accounts Payable
$2.5B
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
3%
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Accounts Payable
$7.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
21%
|
CAGR 10-Years
21%
|
|
|
P
|
Purple Biotech Ltd
TASE:PPBT
|
Accounts Payable
$2.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
15%
|
CAGR 10-Years
21%
|
|
|
Scisparc Ltd
NASDAQ:SPRC
|
Accounts Payable
$208k
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-4%
|
|
|
T
|
Tikun Olam Cannbit Pharmaceuticals Ltd
TASE:TKUN
|
Accounts Payable
₪3.9m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
Innocan Pharma Corp
Glance View
InnoCan Pharma Corp. focuses on the development and sale of CBD-integrated pharmaceuticals including topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The company operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The firm is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.
See Also
What is Innocan Pharma Corp's Accounts Payable?
Accounts Payable
235k
USD
Based on the financial report for Dec 31, 2025, Innocan Pharma Corp's Accounts Payable amounts to 235k USD.
What is Innocan Pharma Corp's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
-15%
Over the last year, the Accounts Payable growth was 27%. The average annual Accounts Payable growth rates for Innocan Pharma Corp have been 35% over the past three years , -15% over the past five years .
